BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Finkelstein FO, Finkelstein SH. The Impact of Anemia Treatment on Health-Related Quality of Life in Patients With Chronic Kidney Disease in the Contemporary Era. Adv Chronic Kidney Dis 2019;26:250-2. [PMID: 31477255 DOI: 10.1053/j.ackd.2019.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Wang Y, Jin H, Wang D, Wei L, Ren K, Mao Y. [Effect of Qingshen Granules on inflammation/hepcidin axis and iron metabolism in patients with renal anemia: a single-center, randomized controlled trial]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:1155-9. [PMID: 31801712 DOI: 10.12122/j.issn.1673-4254.2019.10.04] [Reference Citation Analysis]
2 Lamerato L, James G, van Haalen H, Hedman K, Sloand JA, Tang A, Wittbrodt ET, Yee J. Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study. BMC Nephrol 2022;23:166. [PMID: 35490226 DOI: 10.1186/s12882-022-02778-8] [Reference Citation Analysis]
3 Hao CM, Wittbrodt ET, Palaka E, Guzman N, Dunn A, Grandy S. Understanding Patient Perspectives and Awareness of the Impact and Treatment of Anemia with Chronic Kidney Disease: A Patient Survey in China. Int J Nephrol Renovasc Dis 2021;14:53-64. [PMID: 33654421 DOI: 10.2147/IJNRD.S291393] [Reference Citation Analysis]
4 Fishbane S, Coyne DW. How I treat renal anemia. Blood 2020;136:783-9. [PMID: 32556307 DOI: 10.1182/blood.2019004330] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Grandy S, Palaka E, Guzman N, Dunn A, Wittbrodt ET, Finkelstein FO. Understanding Patient Perspectives of the Impact of Anemia in Chronic Kidney Disease: A United States Patient Survey. Journal of Patient Experience 2022;9:237437352210926. [DOI: 10.1177/23743735221092629] [Reference Citation Analysis]
6 Hussien H, Apetrii M, Covic A. Health-related quality of life in patients with chronic kidney disease. Expert Rev Pharmacoecon Outcomes Res 2021;21:43-54. [PMID: 33213186 DOI: 10.1080/14737167.2021.1854091] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Finkelstein FO. Barriers to optimal peritoneal dialysis. Semin Dial 2020;33:464-7. [PMID: 32924163 DOI: 10.1111/sdi.12912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Hu Z, Tao H, Shi A, Pan J. The efficacy and economic evaluation of roxadustat treatment for anemia in patients with kidney disease not receiving dialysis. Expert Rev Pharmacoecon Outcomes Res 2020;20:411-8. [PMID: 32249625 DOI: 10.1080/14737167.2020.1747436] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
9 Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011) 2021;11:8-25. [PMID: 33777492 DOI: 10.1016/j.kisu.2020.12.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]